What one share of Monte Rosa Therapeutics holds
We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome.
Monte Rosa Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-09-30; the balance sheet is as of 2026-09-30.
| Sales | $0.73 |
|---|---|
| Profit | −$1.36 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$1.81 |
| Dividends | $0.00 |
| Cash and investments | $0.53 |
| Book value | $5.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$23.65 | $2.23 | −$17.43 | — | −$28.91 |
| 2021 | — | −$2.96 | $0.39 | −$2.76 | — | $7.47 |
| 2022 | — | −$2.30 | $0.27 | −$2.23 | — | $5.50 |
| 2023 | $0.00 | −$2.63 | $0.37 | −$1.22 | — | $3.58 |
| 2024 | $1.02 | −$0.98 | $0.05 | $0.51 | — | $3.62 |
| 2025 | $1.49 | −$0.47 | $0.06 | −$0.33 | — | $3.56 |
Common questions about Monte Rosa Therapeutics
How much does one share of Monte Rosa Therapeutics earn?
Over the last 12 months, Monte Rosa Therapeutics lost $1.36 for each share on $0.73 of sales.
Does Monte Rosa Therapeutics pay a dividend?
Monte Rosa Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Monte Rosa Therapeutics’s book value per share?
Monte Rosa Therapeutics’s book value is $5.81 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of September 30, 2026.
How much cash and debt does each share of Monte Rosa Therapeutics have?
Each share of Monte Rosa Therapeutics has $0.53 of cash and investments, as of September 30, 2026.
What is Monte Rosa Therapeutics’s free cash flow per share?
−$1.81 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Monte Rosa Therapeutics bought back shares?
Monte Rosa Therapeutics’s share count rose about 5376% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.